CGBio said it has signed a contract to export $8 million worth of Aileene, its hyaluronic acid (HA) filler, to Australia and New Zealand through Amore Aesthetics.

Amore Aesthetics is a franchise company affiliated with Haus Cosmetics, a leading medical spa brand in Australia and New Zealand. The company has a network of approximately 300 locations in the Oceania region, providing immediate sales and product distribution.

CGBio began the global distribution expansion of Aileene in 2022 and has successfully launched the product in 25 countries.

CGBio plans to expand its market share in Australia and New Zealand through aggressive marketing activities.

Aileene is the world's first multi-layered phasic product that combines the advantages of both viscous monophasic filler and elastic biphasic filler formulations.

It is characterized by low swelling after injection due to optimal hydration, and its visual analog scale score is about half that of other products.

In addition, the degree of modification value, which indicates the degree of modification from natural hyaluronic acid, is lower than 2 percent.

As a result, the filler is close to its natural state, making it safe and easy to modify during the procedure and easy to remove after the procedure.

Aileene filler is divided into three types according to the degree of viscosity and elasticity, and patients can choose the product according to the treatment area.

Vol#1 can be used in soft areas such as the glabella and under-eye hollows, Vol#2 can be used in areas that require volume and continuity such as the frontal cheeks, nasolabial folds, and forehead, and Vol#3 can be used in areas that require volume emphases such as the nose, forehead, and chin.

"As this is Aileene's first entry into the Australian and New Zealand market, we will actively support its successful regional distribution," CGBio CEO Yu Hyun-seung said. "Based on this achievement, we will strengthen our competitiveness in the Oceania region and continue to explore overseas markets to solidify our name as a global regenerative medicine specialist."

According to the Grand View Research, Share & Trends Report, a market research firm, the filler market in Australia and New Zealand was approximately 3.6 trillion won ($2.9 billion) in 2021.